Jump to content

Talk:Tremelimumab

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

NSCLC trial results Feb 2016

[edit]

ASTRAZENECA’S COMBINATION OF DURVALUMAB WITH TREMELIMUMAB SHOWS CLINICAL ACTIVITY IN NON-SMALL CELL LUNG CANCER IRRESPECTIVE OF PD-L1 STATUS. Phase III trials ongoing. - Rod57 (talk) 00:13, 9 February 2016 (UTC)[reply]

As reported at [1], this is a phase Ib study (study 006), which means it's an early exploratory study. According to the content guideline WP:MEDRS, unless there is a particular reason for an exception, this report is completely and utterly irrelevant in this encyclopedic concept space, until further information develops. By convention, people are free to put whatever preliminary speculations or outright rubbish they want on Talk pages. Other editors are then free to come along and criticize the embarassingly poetic fancy of placing premature, naive, buzzing gossip here. This response denounces without reservation this wobbly reference as a (presumably unintentional) bewilderingly misguided promotion of a particular commercial confection, which has not been adequately tested. As a relevant comparative benchmark, there are several approved medications within the immunotherapy concept space, making this reference all the more flagrantly speculative and contextually unscrupulous. FeatherPluma (talk) 17:45, 5 March 2016 (UTC)[reply]